Danske Bank A S Takes $19.43 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY

Danske Bank A S bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 64,555 shares of the biopharmaceutical company’s stock, valued at approximately $19,433,000.

A number of other institutional investors also recently modified their holdings of the business. Brighton Jones LLC bought a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at about $243,000. Geneos Wealth Management Inc. raised its position in shares of Alnylam Pharmaceuticals by 372.3% in the first quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 175 shares in the last quarter. Flow Traders U.S. LLC bought a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at approximately $241,000. Daiwa Securities Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 0.3% in the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock valued at $4,220,000 after buying an additional 35 shares during the period. Finally, NewEdge Advisors LLC grew its position in Alnylam Pharmaceuticals by 70,300.0% during the second quarter. NewEdge Advisors LLC now owns 704 shares of the biopharmaceutical company’s stock worth $229,000 after buying an additional 703 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Raymond James Financial upgraded Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 price objective on the stock in a research note on Monday, August 3rd. Barclays reduced their target price on Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating on the stock in a report on Monday, August 3rd. Morgan Stanley decreased their price target on Alnylam Pharmaceuticals from $400.00 to $300.00 and set an “equal weight” rating on the stock in a research report on Friday, July 31st. BMO Capital Markets began coverage on Alnylam Pharmaceuticals in a research note on Wednesday. They issued an “outperform” rating and a $318.00 price target for the company. Finally, Stifel Nicolaus cut their price objective on shares of Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating for the company in a research report on Friday, July 31st. Four equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $386.62.

Alnylam Pharmaceuticals Stock Down 5.5%

Shares of ALNY opened at $229.30 on Friday. The firm has a 50 day simple moving average of $267.95 and a two-hundred day simple moving average of $297.75. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99. Alnylam Pharmaceuticals, Inc. has a one year low of $197.81 and a one year high of $495.55. The company has a market cap of $30.68 billion, a P/E ratio of 42.62 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The firm had revenue of $1.29 billion for the quarter, compared to the consensus estimate of $1.32 billion. During the same quarter last year, the business posted ($0.51) EPS. The company’s revenue was up 66.9% compared to the same quarter last year. Research analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current fiscal year.

More Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: BMO Capital Markets upgraded Alnylam to “strong buy”, following its initiation of coverage with an “outperform” rating and a $318 price target. The bullish view could support investor confidence by indicating substantial potential upside from recent trading levels. Benzinga analyst coverage report TickerReport Alnylam coverage

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the sale, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. This trade represents a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.